Planegg/Martinsried – The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, with approval of the Supervisory Board decided today that, consistent with the company’s recent decision to focus its development efforts on solid tumors, the MDG1021 development program is to be discontinued.
Recruitment for the Phase I clinical trial of the T cell receptor-modified T cell therapy MDG1021 directed against the antigen HA-1 in patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation, which was initiated at the Leiden University Medical Centre (LUMC) in the Netherlands in mid-2020, will be put on hold with immediate effect. Discussions are ongoing with LUMC regarding the potential assumption of the sponsorship role by the LUMC with continuation of the study under LUMC’s responsibility and return of the development and commercialization rights to the HA-1-specific TCR acquired from LUMC in November 2018.
The impact of Medigene’s discontinuation of the MDG1021 development program will be taken into account when preparing the 2021 financial guidance, which will be published as part of the Annual Report 2020 in March 2021.
emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate